New hope for advanced GI cancers: Triple-Drug combo trial launches

NCT ID NCT03539822

First seen Jan 27, 2026 · Last updated May 12, 2026 · Updated 8 times

Summary

This study tests whether combining two or three drugs (cabozantinib, durvalumab, and tremelimumab) can safely shrink tumors in people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will participate. The goal is to find the best dose and see how many patients respond to treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Kansas Cancer Center

    TERMINATED

    Westwood, Kansas, 66205, United States

Conditions

Explore the condition pages connected to this study.